Search Results - "LORUSSO, D"

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Oaknin, A., Bosse, T.J., Creutzberg, C.L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M.R., Ledermann, J.A., Colombo, N.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing endometrial cancer.•The guideline covers clinical and pathological diagnosis,…”
Get full text

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Ray-Coquard, I, Morice, P, Lorusso, D, Prat, J, Oaknin, A, Pautier, P, Colombo, N

Get full text

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease by Wilson, M.K., Pujade-Lauraine, E., Aoki, D., Mirza, M.R., Lorusso, D., Oza, A.M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S.-J., Ferrero, A.M., Edmondson, R.J., Wimberger, P., Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., Ochiai, K.

“…This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC),…”
Get full text

First line ovarian cancer treatment: Scanning the horizon by Lorusso, D., Daniele, G.

Get full text

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I by Moore, K.N., Oza, A.M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G.E., Banerjee, S., Murphy, C.G., Tanyi, J.L., Hirte, H., Konner, J.A., Lim, P.C., Prasad-Hayes, M., Monk, B.J., Pautier, P., Wang, J., Berkenblit, A., Vergote, I., Birrer, M.J.

“…Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the…”
Get full text

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R.E., Pothuri, B., Ray-Coquard, I., Tan, D.S.P., Bellet, E., Oaknin, A., Ledermann, J.A.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing epithelial ovarian cancer.•The guideline covers clinical and pathological…”
Get full text

Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer by Lorusso, D., Pignata, S.

Get full text

PARPi related toxicities: do we need more appropriate instruments to evaluate it? by Lorusso, D., Pignata, S.

Get full text

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial by Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alia, E.M., Bogner, G., Yoshida, H., Lefeuvre-Plesse, C., Buderath, P., Mosconi, A.M., Lortholary, A., Burges, A., Medioni, J., El-Balat, A., Rodrigues, M., Park-Simon, T.-W., Dubot, C., Denschlag, D., You, B., Pujade-Lauraine, E., Harter, P.

“…In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly…”
Get full text

Immunotherapy and epithelial ovarian cancer: a double-edged sword? by Ray-Coquard, I., Lorusso, D.

Get full text

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer by Vergote, I., González-Martín, A., Ray-Coquard, I., Harter, P., Colombo, N., Pujol, P., Lorusso, D., Mirza, M.R., Brasiuniene, B., Brenton, J.D., Ausems, M.G.E.M., Büttner, R., Lambrechts, D., Vergote, I., Ausems, M., Brasiuniene, B., Brenton, J., Büttner, R., Colombo, N., González-Martín, A., Harter, P., Lambrechts, D., Lorusso, D., Madry, R., Mirza, M.R., Pujol, P., Ray-Coquard, I., Abreu, M., Balboni, S., Banerjee, S., Barberis, M., Barretina Ginesta, M.P., Baurain, J.-F., Bignami, M., Blecharz, P., Bruchim, I., Capilna, M., Cerana, N., Cicchetti, A., Collins, D., Concin, N., D’Incalci, M., de la Motte Rouge, T., De Iaco, P., Denys, H., Doerk, T., Dorum, A., Fidalgo, A.P., Genuardi, M., Gladieff, L., Glasspool, R., Grimm, C., Gultekin, M., Hahnen, E., Hasenburg, A., Hegmane, A., Hogdall, E., Janavicius, R., Jarmalaite, S., Kalachand, R., Kaneva, R., Kilickap, S., Kocian, R., Kolencik, D., Kristeleit, R., Kryzhanivska, A., Leary, A., Lemley, B., Ligtenberg, M., Lord, C.J., Avall-Lundqvist, E., Maenpaa, J., Mahner, S., Marmé, F., Marth, C., McNeish, I., Merkelbach-Bruse, S., Mourits, M., Normanno, N., Oaknin, A., Papdimitriou, C., Penault-Llorca, F., Perrone, A.M., Pignata, S., Pikarsky, E., Rouleau, E., Rubio, M., Schmalfeldt, B., Sehouli, J., Shapira, R., Steffensen, K.D., Sukhin, V., Syrios, J., Szallasi, Z., Taskiran, C., Terzic, M., Tischkowitz, M., Toth, I., Wimberger, P., Witteveen, E.

“…Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of…”
Get full text

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial by Lorusso, D., Ferrandina, G., Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M.T., Savarese, A., Tagliaferri, P., Lombardi, D., Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S.C., Maltese, G., Scambia, G.

“…Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical…”
Get full text

Chemotherapy-free treatments: are we ready for prime time? by Lorusso, D., Pignata, S., Gonzalez-Martin, A.

Get full text

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome) by Lorusso, D, Di Stefano, A, Carone, V, Fagotti, A, Pisconti, S, Scambia, G

“…Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome or hand-to-foot syndrome, is a distinctive and relatively frequent dermatologic toxic…”
Get full text

The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study by Mangili, G., Sigismondi, C., Lorusso, D., Cormio, G., Candiani, M., Scarfone, G., Mascilini, F., Gadducci, A., Mosconi, A.M., Scollo, P., Cassani, C., Pignata, S., Ferrandina, G.

“…Surgery followed by platinum-based chemotherapy is the standard of care for MOGCTs, except for stage IA dysgerminoma and stage IA grade 1 immature teratoma…”
Get full text

Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary by Mangili, G, Ottolina, J, Gadducci, A, Giorda, G, Breda, E, Savarese, A, Candiani, M, Frigerio, L, Scarfone, G, Pignata, S, Rossi, R, Marinaccio, M, Lorusso, D

“…Objective: The aim of this study is to evaluate the long-term outcome of granulosa cell tumour (GCT) of the ovary in a large series of patients treated in MITO…”
Get full text

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial by Mirza, Mansoor R., Benigno, B., Dørum, A., Mahner, S., Bessette, P., Barceló, I. Bover, Berton-Rigaud, D., Ledermann, J.A., Rimel, B.J., Herrstedt, J., Lau, S., du Bois, A., Herráez, A. Casado, Kalbacher, E., Buscema, J., Lorusso, D., Vergote, I., Levy, T., Wang, P., de Jong, F.A., Gupta, D., Matulonis, U.A.

“…Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with…”
Get full text

Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors by Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., Puglisi, F., Pignata, S.

“…•PARP inhibitors have opened the era of targeted therapy in ovarian cancer;•Major therapeutic improvements have been limited to the high grade serous…”
Get full text

Diagnosis of uterine leiomyosarcoma 5 years after magnetic‐resonance‐guided high‐intensity focused ultrasound treatment of fibroid by Ciccarone, F., Biscione, A., Lorusso, D., Zannoni, G. F., Cina, A., Ferrandina, G., Scambia, G., Testa, A. C.

Get full text

MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy by Pignata, S, Califano, D, Lorusso, D, Arenare, L, Bartoletti, M, De Giorgi, U, Andreetta, C, Pisano, C, Scambia, G, Lombardi, D, Farolfi, A, Cinieri, S, Passarelli, A, Salutari, V, De Angelis, C, Mignogna, C, Priolo, D, Capoluongo, E D, Tamberi, S, Scaglione, G L, Arcangeli, V, De Cecio, R, Scognamiglio, G, Greco, F, Spina, A, Turinetto, M, Russo, D, Carbone, V, Casartelli, C, Schettino, C, Perrone, F

“…Immunotherapy combined with chemotherapy significantly improves progression-free survival (PFS) compared to first-line chemotherapy alone in advanced…”
Get more information